KEYMED BIOSCIENCES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.3 HKD | -4.58% |
|
+14.58% | -31.98% |
| Sales 2024 * | 115M 15.82M 124M 1.32B | Sales 2025 * | 573M 79.1M 619M 6.6B | Capitalization | 8.94B 1.23B 9.65B 103B |
|---|---|---|---|---|---|
| Net income 2024 * | -792M -109M -855M -9.12B | Net income 2025 * | -703M -97.02M -759M -8.09B | EV / Sales 2024 * | 69 x |
| Net cash position 2024 * | 1.03B 142M 1.11B 11.88B | Net cash position 2025 * | 946M 131M 1.02B 10.89B | EV / Sales 2025 * | 13.9 x |
| P/E ratio 2024 * |
-11
x | P/E ratio 2025 * |
-12.8
x | Employees | 897 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 56.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.30% | ||
| 1 week | +14.58% | ||
| Current month | -1.47% | ||
| 1 month | +6.20% | ||
| 3 months | +0.30% | ||
| 6 months | -41.40% | ||
| Current year | -31.98% |
1 week
29.95
36.90
1 month
26.6036.90
Current year
26.6049.20
1 year
26.6065.60
3 years
16.9082.85
5 years
16.9082.85
10 years
16.9082.85
| Managers | Title | Age | Since |
|---|---|---|---|
Bo Chen
CEO | Chief Executive Officer | 50 | 23/18/23 |
Yanrong Zhang
DFI | Director of Finance/CFO | 36 | 01/20/01 |
Joy Yan
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheuk Kin Law
BRD | Director/Board Member | 61 | 01/21/01 |
Yang Ke
BRD | Director/Board Member | 68 | 03/21/03 |
Bo Chen
CEO | Chief Executive Officer | 50 | 23/18/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.54% | 4 M€ | -27.92% | ||
| 0.02% | 4 M€ | -4.41% | - | |
| 0.02% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 33.3 | -4.58% | 1 328 000 |
| 26/24/26 | 34.9 | -0.14% | 1,168,100 |
| 25/24/25 | 34.95 | +3.86% | 1,411,000 |
| 24/24/24 | 33.65 | +4.18% | 1,408,000 |
| 23/24/23 | 32.3 | +10.81% | 1,179,500 |
Delayed Quote Hong Kong S.E., April 29, 2024 at 01:17 pm IST
More quotes
Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.31
CNY
Average target price
54.48
CNY
Spread / Average Target
+68.63%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.98% | 1.23B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.76% | 22.15B | |
| -17.37% | 21.02B | |
| -8.28% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2162 Stock
